|1|Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(Ar)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? (25651409)
Kirchin M.A.... Pirovano G.
|2|Nephrogenic Systemic Fibrosis Risk After Liver Magnetic Resonance Imaging With Gadoxetate Disodium in Patients With Moderate to Severe Renal Impairment: Results of a Prospective, Open-Label, Multicenter Study. (25756684)
Lauenstein T.... Endrikat J.
|3|Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. (24706993)
Bernstein E.J.... Kay J.
|4|Substitution of gadolinium ethylenediaminetetraacetate with phosphites: towards gadolinium deposit in nephrogenic systemic fibrosis. (24132302)
Gao S.... Zhou Z.H.
|5|Nephrogenic systemic fibrosis in denmark- a nationwide investigation. (24349178)
Elmholdt T.R.... Pedersen M.
|6|Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk. (22316507)
Nicholas B.A.... Ponsky L.E.
|7|Understanding nephrogenic systemic fibrosis. (23193473)
Chopra T.... Panesar M.
|8|Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. (21036418)
Christensen K.N.... Pittelkow M.R.
|9|Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update. (21471962)
Jalandhara N.... Batuman V.
|10|Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. (21414498)
Nazarian R.M.... Duncan L.M.
|11|Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. (21724294)
Girardi M.... Cowper S.E.
|12|"Carcinoid-like" tricuspid valvulopathy associated with nephrogenic systemic fibrosis. (21366687)
Gharacholou S.M.... Ammash N.M.
|13|Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. (19896750)
High W.A.... Jackson B.P.
|14|Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. (20032228)
Stratta P.... Fenoglio R.
|15|Nephrogenic systemic fibrosis: a review. (20677539)
Chen A.Y.... Heffernan M.P.
|16|Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. (19341434)
Deng A.... Kao G.
|17|Nephrogenic systemic fibrosis in a patient with spinal cord injury: a unique case presentation. (21145526)
Knapp B.A.... Sepahpanah F.
|18|NFI_B activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. (20959327)
Del Galdo F.... Jimenez S.A.
|19|MRI safety: nephrogenic systemic fibrosis and other risks. (20542435)
Gauden A.J.... Drummond K.J.
|20|Estimates of risk, empirical treatment observations, and unexpected laboratory findings reveal the complexity of nephrogenic systemic fibrosis. (19841408)
|21|Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. (19151610)
Hope T.A.... Weil E.
|22|Effects of gadolinium contrast agents in naA^ve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. (19160079)
Grant D.... vhaug D.
|23|Nephrogenic systemic fibrosis: clinical picture and treatment. (19744598)
Marckmann P.... Skov L.
|24|High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. (19457816)
Bridges M.D.... Fitzpatrick P.M.
|25|Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. (19188312)
Perez-Rodriguez J.... Bluemke D.A.
|26|Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. (19744600)
IdAce J.M.... Corot C.
|27|Nephrogenic systemic fibrosis and management of high-risk patients. (19375360)
Altun E.... Cakit C.
|28|Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. (19789237)
Hope T.A.... Brasch R.C.
|29|Nephrogenic systemic fibrosis: more questions and some answers. (18688172)
Morcos S.K.... Thomsen H.S.
|30|Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. (18635232)
Bhave G.... Chang S.S.
|31|Nephrogenic systemic fibrosis: a new concern for rheumatologists. (18756271)
|32|An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. (18328659)
|33|Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. (18401336)
Swaminathan S.... Shah S.V.
|34|Nephrogenic systemic fibrosis and gadolinium: a perfect storm. (18806157)
|35|Epoetin and nephrogenic systemic fibrosis. (18158932)
|36|Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. (18690983)
|37|Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. (18324398)
Weigle J.P.... Broome D.R.
|38|Nephrogenic systemic fibrosis associated with gadolinium use. (18400614)
Chao C.C.... Hsieh S.T.
|39|Treatment of nephrogenic systemic fibrosis with Re-PUVA. (18625379)
Duffy K.L.... Powell D.
|40|Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis. (19385151)
Padilla-Thornton A.... Forster B.B.
|41|Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. (18425843)
Sieber M.A.... Pietsch H.
|42|Gadolinium-associated nephrogenic systemic fibrosis. (19920874)
McKoy J.M.... Bennett C.L.
|43|A timely reminder about an evolving clinical entity: nephrogenic systemic fibrosis and gadolinium use in CKD. (17498132)
|44|Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. (17602192)
Pieringer H.... Biesenbach G.
|45|Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. (17457808)
|46|Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. (17712863)
Thakral C.... Abraham J.L.
|47|Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate. (17504326)
Hedley A.J.... Ierino F.L.
|48|The role of the hospital dermatologist in the diagnosis and treatment of calciphylaxis and nephrogenic systemic fibrosis. (18070683)
Weenig R.H.... el-Azhary R.
|49|Nephrogenic systemic fibrosis--the beginning of the end? (17572281)
|50|Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. (16427988)
Kucher C.... Xu X.